Telix Pharmaceuticals Ltd — AGM Information 2023

May 23, 2023

==> picture [144 x 59] intentionally omitted <==

Annual General Meeting of Shareholders

Telix Pharmaceuticals (ASX:TLX) 11.00am AEST 24 May 2023

==> picture [457 x 540] intentionally omitted <==

Important information

This presentation is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This presentation contains summary information about Telix Pharmaceuticals Limited (ACN 616 620 369) and its related bodies corporate (together, Telix) and Telix's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with Telix's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au. This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire Telix shares or other securities.

Telix products are currently investigational use only unless indicated and are subject to future regulatory developments and product approvals. Except for Illuccix® (Ga-68 gozetotide injection), none of the other products have received a marketing authorisation in any jurisdiction. Registrations vary country to country. Some statements about products, registered product indications or procedures may differ in certain countries. Therefore, always consult the country-specific product information, package leaflets or instructions for use. Any content relating to third party products is based on publicly available data and is accurate at the date of presentation.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Telix or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of Telix or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to Telix, including statements regarding Telix's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to Telix's business and operations, market conditions, results of operations and financial conditions, products in research and risk management practices. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", “project,” "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on Telix's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect Telix's business and operations in the future. Telix does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties, and assumptions and other important factors, many of which are beyond the control of Telix, that could cause the actual results, performances or achievements of Telix to be materially different to future results, performances or achievements expressed or implied by the statements. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, and Telix’s ability to protect its patents and other intellectual property.

The audience should read this presentation together with our material risks, as disclosed in our most recently filed reports with the ASX and on our website. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, Telix does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

Copyright and Trademarks

©2023 Telix Pharmaceuticals Limited. Except where otherwise noted, brand names designated by a ™or ® throughout this presentation are trademarks either owned by and/or licensed to Telix (all rights reserved).

==> picture [73 x 30] intentionally omitted <==

==> picture [960 x 34] intentionally omitted <==

----- Start of picture text -----

2
----- End of picture text -----

H Kevin McCann AO Chairman

==> picture [291 x 290] intentionally omitted <==

==> picture [73 x 30] intentionally omitted <==

3

Board of Directors

==> picture [129 x 129] intentionally omitted <==

==> picture [121 x 129] intentionally omitted <==

==> picture [128 x 128] intentionally omitted <==

==> picture [129 x 129] intentionally omitted <==

==> picture [128 x 129] intentionally omitted <==

==> picture [129 x 129] intentionally omitted <==

H Kevin McCann AO Christian Behrenbruch

H Kevin McCann AO Christian Andreas Kluge Mark Nelson Tiffany Olson Jann Skinner Behrenbruch Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Director and Managing Director Director Director Director Director Chairman and Group CEO

Note: Dr Andreas Kluge is currently on a leave of absence from the Board of Directors, for a period of approximately six months.

==> picture [73 x 30] intentionally omitted <==

4

Meeting agenda

01

Chairman’s address

02

CEO’s address

03

Formal items of business, including voting and questions

==> picture [73 x 30] intentionally omitted <==

5

==> picture [144 x 59] intentionally omitted <==

Video

6

==> picture [73 x 30] intentionally omitted <==

7

==> picture [73 x 30] intentionally omitted <==

8

Delivering to our growth strategy

Our key accomplishments in 2022

==> picture [109 x 110] intentionally omitted <==

==> picture [108 x 108] intentionally omitted <==

==> picture [108 x 108] intentionally omitted <==

==> picture [109 x 109] intentionally omitted <==

Commercialise the diagnostics portfolio

Unlock value in the therapeutic pipeline

Strengthen supply chain and manufacturing

Expand the pipeline

• $247M revenue from Illuccix U.S., sales since launch in April 2022

• ProstACT SELECT study fully enrolled

   - Olaratumab (TLX300) inlicensed and demonstrated proof of concept
  

  • U.S. distribution network expanded to 202 radiopharmacies

• Manufacturing scale-up to support ProstACT GLOBAL

• Illuccix label expansion

  • Buildout of Brussels South production facility

  • • Acquisition of Optimal Tracers

• First patients dosed in STARLITE-2 (TLX250)

• EU / UK submissions filed

• Development of AI platform and acquisition of Dedicaid

• ZIRCON Phase III readout

• STARSTRUCK study ethics approval (TLX250 combo)

• • IPAX-2 initiated based on positive results from IPAX-1

• Commercialising two additional products

• Multiple collaboration partnerships driving “future frontier” development

• Multiple clinical and commercial supply agreements

==> picture [73 x 30] intentionally omitted <==

==> picture [960 x 34] intentionally omitted <==

----- Start of picture text -----

9
----- End of picture text -----

Leadership in urologic oncology Building deep relationships with the Illuccix customer

Supporting the urologic patient across the continuum of imaging, surgery and therapy

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 73] intentionally omitted <==

Bladder cancer

Prostate Kidney cancer cancer

==> picture [305 x 131] intentionally omitted <==

Artificial Intelligence platform: Reader and clinical decision support > automation, longitudinal data, disease prediction

==> picture [73 x 30] intentionally omitted <==

==> picture [960 x 34] intentionally omitted <==

----- Start of picture text -----

10
----- End of picture text -----

Transition to a financially sustainable company

Continual improvement across key financial metrics

==> picture [888 x 306] intentionally omitted <==

----- Start of picture text -----

Key expenditure ($M) and
Adjusted EBITDAR ($M) percentage of sales
30.0 150%
40.0
130%
36.7 25.0 27.4
30.0
112% 110%
23.1 22.6
20.0
20.0 20.6 90%
22.1
18.3
15.0 70%
10.0 14.4
10.0 22.1 20.4 24.0 20.9 50%
- 29% 28% 30%
5.0 10.4 37%
(10.0) (11.1) 10%
(17.3)
0.0 -10%
(20.0) Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023
Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023
Operating expenditure (SG&A) R&D expenditure (Pipeline) % of sales
----- End of picture text -----

==> picture [73 x 30] intentionally omitted <==

==> picture [960 x 34] intentionally omitted <==

----- Start of picture text -----

11
----- End of picture text -----

Developing a world-class organisation

We have effectively scaled to optimise development and drive commercial success

==> picture [508 x 346] intentionally omitted <==

----- Start of picture text -----

Commercial
Development and Research & Early-Stage Clinical
Development
commercialisation Innovation Development
(Phase III)
Clinical Medical Alliance
Operations Affairs Management
Global centres
of Excellence
Manufacturing Regulatory
and Operations and Quality
Operating Regions:
Americas, EMEA Commercial Functions (Sales and Marketing, Market Access) and
and APAC Regional Operations (Product Delivery)
Global Services Finance / HR / Legal / Business Development / Communications
----- End of picture text -----

==> picture [346 x 191] intentionally omitted <==

==> picture [960 x 34] intentionally omitted <==

----- Start of picture text -----

12
----- End of picture text -----

Four major focus areas for 2023

Value creating catalysts across the imaging and therapeutic pipeline

==> picture [194 x 194] intentionally omitted <==

----- Start of picture text -----

Illuccix® -
continued revenue
growth and global
rollout
----- End of picture text -----

==> picture [666 x 195] intentionally omitted <==

----- Start of picture text -----

ProstACT
New Drug
GLOBAL patient
Biologics License
Application (NDA)
recruitment and
for brain cancer Application (BLA)
ProstACT
submission for
imaging
SELECT/TARGET
TLX250-CDx
(TLX101-CDx)
data readouts
----- End of picture text -----

==> picture [73 x 30] intentionally omitted <==

13

Investor contact Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixpharma.com

==> picture [291 x 290] intentionally omitted <==

Authorised for release to the ASX by the Telix Board of Directors

==> picture [73 x 30] intentionally omitted <==

14